Quoin pharmaceuticals announces pricing of $16.8 million upsized public offering

Ashburn, va., aug. 05, 2022 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 11,050,000,000 ordinary shares represented by 2,210,000 american depositary shares at a purchase price of $5.00 per ads and pre-funded warrants to purchase 5,750,000,000 ordinary shares represented by 1,150,000 american depositary shares at a per pre-funded warrant price of $4.9999 (with each ads and pre-funded warrant accompanied by an ordinary warrant) for an aggregate gross proceeds of $16.8 million.
QNRX Ratings Summary
QNRX Quant Ranking